国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2013年
20期
1581-1585
,共5页
非小细胞肺癌%表皮生长因子受体-酪氨酸激酶抑制剂%耐药机制
非小細胞肺癌%錶皮生長因子受體-酪氨痠激酶抑製劑%耐藥機製
비소세포폐암%표피생장인자수체-락안산격매억제제%내약궤제
Non-small cell lung cancer%Epidermal growth factor receptor-tyrosine kinase inhibitor%Resistance mechanism
以厄洛替尼、吉非替尼为代表的表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂(TKI)靶向治疗近年来为存在EGFR突变的非小细胞肺癌(NSCLC)患者带来了很大获益.肺癌对EGFR-TKI原发及继发性耐药是导致此类药物最终治疗失败的原因.本文就NSCLC对EGFR-TKI分子耐药机制及耐药后治疗策略进行综述.
以阨洛替尼、吉非替尼為代錶的錶皮生長因子受體(EGFR)-酪氨痠激酶抑製劑(TKI)靶嚮治療近年來為存在EGFR突變的非小細胞肺癌(NSCLC)患者帶來瞭很大穫益.肺癌對EGFR-TKI原髮及繼髮性耐藥是導緻此類藥物最終治療失敗的原因.本文就NSCLC對EGFR-TKI分子耐藥機製及耐藥後治療策略進行綜述.
이액락체니、길비체니위대표적표피생장인자수체(EGFR)-락안산격매억제제(TKI)파향치료근년래위존재EGFR돌변적비소세포폐암(NSCLC)환자대래료흔대획익.폐암대EGFR-TKI원발급계발성내약시도치차류약물최종치료실패적원인.본문취NSCLC대EGFR-TKI분자내약궤제급내약후치료책략진행종술.
In recent years,epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) erlotinib and gefitinib have shown dramatic effects against EGFR mutant non-small cell lung cancer.However,tumor become resistant to EGFR-TKI by various mechanisms and may finally lead to failure in disease control.In this paper,we reviews mechanisms of EGFR-TKI resistance in non-small cell lung cancer and therapeutic strategies to overcome EGFR-TKI resistance.
